Abstract 188P
Background
Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLS) and B cells. However, the cellular and molecular mechanisms underlying these clinical associations have not been elucidated yet.
Methods
TME composition and TLS quantification were assessed by sequential IHC with αCD3, αCD20, αCD23 and αCD68 antibodies on specimens obtained from patients with primary or locally recurrent STS enrolled and treated at the Careggi Hospital (RESEARCH study). TME transcriptomic profiling was performed using the nCounter Immunology Panel by NanoString. RNA-sequencing and clinical data for 206 STS patients were retrieved from the TCGA SARC project.
Results
IHC of 23 treatment-naïve STS specimens showed higher TLS density and incidence in the group of non-recurrent patients (11/15) compared to patients developing recurrence (2/8; P=0.039). CD8+ T cell, CD20+ B cell and CD23+ follicular dendritic cell densities are higher in the TME of TLS+ STS. CD20 and CD23 (but not CD8) expression is associated to improved recurrence-free survival (RFS) and overall survival (OS) in our cohort. Transcriptomic analysis of 31 treatment-naïve STSs showed that high expression of genes discriminating for germinal center (GC) B cells correlated to the upregulation of Th17-related genes, and decreased expression of M2-like tumor-associated macrophages (TAMs)-related genes. High expression of GC B cell- and Th17 differentiation-related signatures showed associations to longer RFS in our cohort, and to improved OS in the TCGA SARC cohort. Analysis of 5 samples obtained after neoadjuvant radiotherapy (RT) showed reduced expression of IL17A and GC B-related genes while increased TAM-related gene expression, compared to paired biopsies obtained before RT.
Conclusions
Our data identified a prognostic value for Th17-related genes, suggest a potential crosstalk between GC B cells and Th17 cells in coordinating antitumor immune responses, and a potential role for M2-like TAMs (and RT) in inhibiting TLS formation in STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response
Presenter: Ines Pires da Silva
Session: Poster session 08
134P - Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)
Presenter: Arutha Kulasinghe
Session: Poster session 08
135P - Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting
Presenter: Adrien Costantini
Session: Poster session 08
136P - Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study
Presenter: Benoit You
Session: Poster session 08
137P - Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker
Presenter: Sebastien Salas
Session: Poster session 08
138P - Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics
Presenter: Amelie Franken
Session: Poster session 08
139P - Multimodal prognosis modeling of advanced NSCLC treated with first-line immunochemotherapy: Integrating genomic and microenvironmental data
Presenter: Yi Hu
Session: Poster session 08
140P - Mining metastatic lymph nodes for response to immune checkpoint therapy in non-small cell lung cancer
Presenter: Elena Donders
Session: Poster session 08
141P - Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study
Presenter: Benedetta Conte
Session: Poster session 08